April 4, that modernizes and improves Medicare Advantage (MA), Medicare Prescription Drug Benefit (Part D), Medicare cost ...

A study comparing artificial intelligence (AI)-driven clinical recommendations to physician decision-making for common acute complaints in a virtual primary care setting found that AI support has the ...

Diabetes patients on dulaglutide (Trulicity) had better glycemic control and more weight loss if they switched to tirzepatide (Mounjaro) rather than increasing the dose of the earlier-generation GLP-1 ...

For patients with inadequately controlled type 2 diabetes receiving dulaglutide, switching to tirzepatide is associated with additional hemoglobin A1c (HbA1c) reduction and weight loss compared with ...

The study finds better A1c lowering and weight reduction, but an expert clinician says practical issues may pose barriers.

Jim Cramer in a latest program on CNBC urged investors to start accepting the reality of the new economic system under ...

Health care stocks have outperformed so far in 2025 despite uncertainty surrounding the new Donald Trump administration. Health care stocks can often be a solid defensive play in an uncertain economy.

The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.

Originally developed to treat Type 2 diabetes, glucagon-like peptide 1 (GLP-1s) are now being studied to explore their ...

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

The recent uptick and rise in popularity of GLP-1 drugs for addressing weight loss and obesity has led to an increase in U.S. litigation ...